Opko Health, Inc. Announces Completion of Enrollment for Its Phase III Clinical Trial of Bevasiranib for Treatment of AMD

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (AMEX:OPK) announced today that it has completed enrollment in the Company’s Phase III clinical trial of bevasiranib for the treatment of wet age-related macular degeneration (wet AMD). The multi-national study has enrolled more than 330 patients and is designed to assess the efficacy and safety of bevasiranib administered every 8 or 12 weeks in preventing vision loss due to wet AMD.

Back to news